AR variants (AR-Vs), which are unconventional nuclear hormone receptor family transcription factors, have their transcriptional activity enhanced by DNA-PKcs binding to the transcriptional elements and DNA-PKcs also participates in the mRNA processing of AR-Vs together with RNA-binding protein RBMX, eventually leading to increased expression of AR-Vs in advanced prostate cancer and resistance to traditional AR-targeted therapy [107]. This evidence concerns the gene PRKDC and prostate carcinoma.